REFERENCES
1. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A
review. Clin Immunol. 2020; 215:108427.
2. Zheng Y, Sun LJ, Xu M, Pan J, Zhang YT, Fang XL, Fang Q, Cai HL.
Clinical characteristics of 34 COVID-19 patients admitted to intensive
care unit in Hangzhou, China. J Zhejiang Univ Sci B.2020;21(5):378-387.
3. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory
Responses: From Mechanisms to Potential Therapeutic Tools. Virol
Sin. 2020; 3:1-6.
4. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, Su X, Cao B. SARS-CoV-2
and viral sepsis: observations and hypotheses. The Lancet. 2020;
395(10235):1517-1520.
5. Delgado-Roche L, Mesta F. Oxidative Stress as Key Player in Severe
Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection. Arch
Med Res. 2020;51(5):384-387.
6. Dolmatova EV, Wang K, Mandavilli R, Griendling KK. The effects of
sepsis on endothelium and clinical implications. Cardiovascular
Research. 2020; 26:cvaa070.
7. Merad M and Martin JC. Pathological inflammation in patients with
COVID-19: a key role for monocytes and macrophages. Nature Reviews
Immunology . 2020; 20: 355–362.
8. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R,
Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H.
Endothelial cell infection and endotheliitis in COVID-19. The
Lancet. 2020; 395(10234):1417-1418.
9. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G.
Is COVID-19 an endothelial disease? Clinical and basic evidence. 2020;Preprints , 2020040204.
10. Chiappelli F, Khakshooy A, Greenberg G. CoViD-19 Immunopathology and
Immunotherapy. Bioinformation. 2020;16(3):219-222.
11. Wu R, Wang L, Kuo HD, Shannar A, Peter R, Chou PJ, Li S, Hudlikar R,
Liu X, Liu Z, Poiani GJ, Amorosa L, Brunetti L, Kong AN. An Update on
Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep .
2020; 11:1-15.
12. Weber D, Davies MJ, Grune T. Determination of protein carbonyls in
plasma, cell extracts, tissue homogenates, isolated proteins: Focus on
sample preparation and derivatization conditions. Redox Biol.2015; 5:367-380.
13. Bost P, Giladi A, Liu Y, Bendjelal Y, Xu G, David E, Blecher-Gonen
R, Cohen M, Medaglia C, Li H, Deczkowska A, Zhang S, Schwikowski B,
Zhang Z, Amit I. Host-Viral Infection Maps Reveal Signatures of Severe
COVID-19 Patients. Cell. 2020; 181(7):1475-1488.e12.
14. Perrone LA, Belser JA, Wadford DA, Katz JM, Tumpey TM. Inducible
nitric oxide contributes to viral pathogenesis following highly
pathogenic influenza virus infection in mice. J. Infect. Dis.2013; 207:1576–1584.
15. Wang JZ, Zhang RY and Bai J. An anti-oxidative therapy for
ameliorating cardiac injuries of critically ill COVID-19-infected
patients. Int J Cardiol. 2020 Aug 1; 312: 137–138.
16. Liu Y, Zhang C, Huang F, Yang Y, Wang F, Yuan J, Zhang Z, Qin Y, Li
X, Zhao D, et al., Elevated plasma levels of selective cytokines in
COVID-19 patients reflect viral load and lung injury. National
Science Review , 2020; 7(6):1003–1011.
17. Derouiche S. Oxidative Stress Associated with SARS-Cov-2 (COVID-19)
Increases the Severity of the Lung Disease - A Systematic Review.J Infect Dis Epidemiol. 2020; 6:121
18. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue
J, Crawford JM, Daßler-Plenker J, Guerci P, Huynh C, Knight JS, Loda M,
Looney MR, McAllister F, Rayes R, Renaud S, Rousseau S, Salvatore S,
Schwartz RE, Spicer JD4, Yost CC, Weber A, Zuo Y, Egeblad M. Targeting
potential drivers of COVID-19: Neutrophil extracellular traps. J
Exp Med. 2020; 217(6): 20200652.
19. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M,
Levantovsky R, Malle L, Moreira A, Park MD, Pia L, Risson E, Saffern M,
Salomé B, Esai Selvan M, Spindler MP, Tan J, van der Heide V, Gregory
JK, Alexandropoulos K, Bhardwaj N, Brown BD, et al., and Sinai
Immunology Review Project. Immunology of COVID-19: Current State of the
Science. Immunity. 2020;52(6):910-941.
20. Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y, Dai T, Zhang T, Lai Y,
Wang J, Liu Z, He A, O’Dwyer M, Hu J. COVID-19 infection induces readily
detectable morphological and inflammation-related phenotypic changes in
peripheral blood monocytes, the severity of which correlate with patient
outcome. medRxiv . 2020. 20042655.
21. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19:
Immunology and treatment options. Clin Immunol. 2020; 215:108448.
22. Dutta A, Das A, Kondziella D, and Stachowiak MK. Bioenergy Crisis in
Coronavirus Diseases? Brain Sci . 2020; 10:277.
23. Salimi S, and Hamlyn JM. COVID-19 and Crosstalk with the Hallmarks
of Aging. J Gerontol A Biol Sci Med Sci , 2020, Vol. XX, No. XX,
1–8.
24. Taghizadeh-Hesarya F and Akbaria H. The powerful immune system
against powerful COVID-19: A hypothesis. Medical Hypotheses .
2020; 140:109762.
25. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et
al. Dysregulated Type I interferon and inflammatory monocyte-macrophage
responses cause lethal pneumonia in SARS-CoV-infected mice. Cell
Host Microbe . 2016;19(2):181–93.
26. Qianwen Zhao, Meng Meng, Rahul Kumar, Yinlian Wu, Jiaofeng Huang,
Yunlei Deng, Zhiyuan Weng, and Li Yanga. Lymphopenia is associated with
severe coronavirus disease 2019 (COVID-19) infections: A systemic review
and meta-analysis. Int J Infect Dis. 2020; 96: 131–135.
27. Zini G, Bellesi S, Ramundo F, & d’Onofrio G. Morphological
anomalies of circulating blood cells in COVID-19. American Journal
of Hematology. 2020. doi:10.1002/ajh.25824
28. Terry LNR, Mediaceja VO, Noa LMV, Sánchez FP. (2016). Valor
semiológico del frotis de sangre periférica en el estudio de las
enfermedades virales. Revista latinoamericana de patología clínica y
medicina de laboratorio. Disponible en:
https://www.medigraphic.com/pdfs/patol/pt-2016/pt163h.pdf
29. Zheng M, Gao Y, Wang G. et al. Functional exhaustion of antiviral
lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020; 17,
533–535.
30. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, Zhang Y.
Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19
Pneumonia. The Journal of Infectious Diseases. 2020;
doi:10.1093/infdis/jiaa150.
31. Singh A, Sood N, Narang V, & Goyal A. Morphology of
COVID-19-affected cells in peripheral blood film. BMJ case
reports. 2020; 13(5): e236117.
32. Wang J, Jiang M, Chen X, & Montaner LJ. Cytokine storm and
leukocyte changes in mild versus severe SARS‐CoV‐2 infection: Review of
3939 COVID‐19 patients in China and emerging pathogenesis and therapy
concepts. Journal of Leukocyte Biology. 2020
doi:10.1002/jlb.3covr0520-272r